APRE
Aprea Therapeutics, Inc.$0.75+0.01 (+1.53%)Prev Close$0.74·MCap$9.6M·P/E—·Vol187.8K·Yield—
▲
Buys (12M)
4
$60.9K
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$60.9K
●
Active Insiders
3
last 12 mo
Over the past 12 months, insider activity at Aprea Therapeutics, Inc. (APRE) has been exclusively buying, with 4 insider purchases totaling $60.9K and 0 insider sales totaling $0.00. The most recent insider transaction was by Gilad Oren (President/CEO), who purchased $25.0K worth of shares on Jan 30, 2026. Aprea Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $9.6M.
APRE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Gilad Oren | President/CEO | Buy | 28,100 | $0.89 | $25.0K | 0 |
| Jan 30, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $0.89 | $5.1K | 0 |
| Dec 10, 2025 | Duey Marc | Director | Buy | 21,459 | $1.16 | $25.0K | 0 |
| Dec 10, 2025 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,000 | $1.17 | $5.8K | 0 |
| Apr 3, 2025 | Gilad Oren | President/CEO | Buy | 5,500 | $1.84 | $10.1K | 0 |
| Oct 23, 2024 | Gilad Oren | President/CEO | Buy | 500 | $3.92 | $2.0K | 0 |
| Oct 18, 2024 | Duey Marc | Director | Sell | 6,462 | $4.58 | $29.6K | 0 |
| Oct 16, 2024 | Duey Marc | Director | Buy | 30,000 | $4.39 | $131.7K | 0 |
| Oct 15, 2024 | Gilad Oren | President/CEO | Buy | 250 | $2.90 | $725.00 | 0 |
| Oct 14, 2024 | Duey Marc | Director | Buy | 190 | $2.58 | $490.20 | 0 |
| Oct 11, 2024 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 50 | $2.46 | $123.19 | 0 |
| Oct 11, 2024 | Seizinger Bernd R. | Director | Buy | 10,000 | $2.68 | $26.8K | 0 |
| Oct 10, 2024 | Gilad Oren | President/CEO | Buy | 1,150 | $2.58 | $3.0K | 0 |
| Oct 10, 2024 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 450 | $2.61 | $1.2K | 0 |
| Mar 13, 2024 | Gilad Oren | President, CEO | Buy | 2,000 | $7.29 | $14.6K | 0 |
| Mar 13, 2024 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 1,010 | $7.29 | $7.4K | 0 |
| Mar 13, 2024 | Seizinger Bernd R. | Director | Buy | 6,860 | $7.29 | $50.0K | 0 |
| Jun 6, 2023 | Seizinger Bernd R. | Director | Buy | 10,097 | $3.66 | $37.0K | 0 |
| Jun 3, 2022 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 32,667 | $0.80 | $26.3K0.5% OS | 0 |
| Jun 3, 2022 | Coiante Scott M | SVP, Chief Financial Officer | Sell | 35,284 | $0.80 | $28.4K0.5% OS | 0 |
| Jun 3, 2022 | Korbel Gregory Alan | SVP, Chief Operating Officer | Sell | 8,390 | $0.81 | $6.8K | 0 |
| Jun 3, 2022 | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 65,770 | $0.81 | $52.9K1.0% OS | 0 |
| May 18, 2022 | SCHADE CHRISTIAN S | Chairman & CEO | Buy | 37,500 | $0.64 | $24.1K0.6% OS | 0 |
| May 18, 2022 | Seizinger Bernd R. | Director | Buy | 50,000 | $0.71 | $35.5K0.8% OS | 0 |
| Mar 10, 2022 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,989 | $1.82 | $3.6K | 0 |
| Feb 28, 2022 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 36,000 | $1.73 | $62.3K0.6% OS | 0 |
| Feb 25, 2022 | Coiante Scott M | SVP, Chief Financial Officer | Sell | 14,817 | $1.74 | $25.8K | 0 |
| Feb 25, 2022 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,326 | $1.74 | $2.3K | 0 |
| Feb 25, 2022 | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 21,644 | $1.74 | $37.7K | 0 |
| Dec 1, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $3.96 | $108.9K | 0 |
| Nov 1, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $5.00 | $137.5K | 0 |
| Oct 1, 2021 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 50,000 | $4.89 | $244.5K0.8% OS | 0 |
| Oct 1, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $4.89 | $134.5K | 0 |
| Sep 20, 2021 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 25,000 | $4.97 | $124.3K | 0 |
| Sep 20, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 32,960 | $4.97 | $163.9K0.5% OS | 0 |
| Sep 16, 2021 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 15,968 | $4.68 | $74.7K | 0 |
| Sep 10, 2021 | Korbel Gregory Alan | Chief Business Officer | Sell | 1,724 | $4.59 | $7.9K | 0 |
| Aug 25, 2021 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 9,032 | $3.98 | $35.9K | 0 |
| Aug 25, 2021 | Coiante Scott M | SVP, Chief Financial Officer | Sell | 7,534 | $3.98 | $30.0K | 0 |
| Aug 25, 2021 | Korbel Gregory Alan | Chief Business Officer | Sell | 1,149 | $3.98 | $4.6K | 0 |
APRE Insider Buying Activity
The following table shows recent insider purchases of Aprea Therapeutics, Inc. (APRE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Gilad Oren | President/CEO | Buy | 28,100 | $0.89 | $25.0K | 0 |
| Jan 30, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $0.89 | $5.1K | 0 |
| Dec 10, 2025 | Duey Marc | Director | Buy | 21,459 | $1.16 | $25.0K | 0 |
| Dec 10, 2025 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,000 | $1.17 | $5.8K | 0 |
| Apr 3, 2025 | Gilad Oren | President/CEO | Buy | 5,500 | $1.84 | $10.1K | 0 |
| Oct 23, 2024 | Gilad Oren | President/CEO | Buy | 500 | $3.92 | $2.0K | 0 |
| Oct 16, 2024 | Duey Marc | Director | Buy | 30,000 | $4.39 | $131.7K | 0 |
| Oct 15, 2024 | Gilad Oren | President/CEO | Buy | 250 | $2.90 | $725.00 | 0 |
| Oct 14, 2024 | Duey Marc | Director | Buy | 190 | $2.58 | $490.20 | 0 |
| Oct 11, 2024 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 50 | $2.46 | $123.19 | 0 |
| Oct 11, 2024 | Seizinger Bernd R. | Director | Buy | 10,000 | $2.68 | $26.8K | 0 |
| Oct 10, 2024 | Gilad Oren | President/CEO | Buy | 1,150 | $2.58 | $3.0K | 0 |
| Oct 10, 2024 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 450 | $2.61 | $1.2K | 0 |
| Mar 13, 2024 | Gilad Oren | President, CEO | Buy | 2,000 | $7.29 | $14.6K | 0 |
| Mar 13, 2024 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 1,010 | $7.29 | $7.4K | 0 |
| Mar 13, 2024 | Seizinger Bernd R. | Director | Buy | 6,860 | $7.29 | $50.0K | 0 |
| Jun 6, 2023 | Seizinger Bernd R. | Director | Buy | 10,097 | $3.66 | $37.0K | 0 |
| May 18, 2022 | SCHADE CHRISTIAN S | Chairman & CEO | Buy | 37,500 | $0.64 | $24.1K0.6% OS | 0 |
| May 18, 2022 | Seizinger Bernd R. | Director | Buy | 50,000 | $0.71 | $35.5K0.8% OS | 0 |
APRE Insider Selling Activity
The following table shows recent insider sales of Aprea Therapeutics, Inc. (APRE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 18, 2024 | Duey Marc | Director | Sell | 6,462 | $4.58 | $29.6K | 0 |
| Jun 3, 2022 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 32,667 | $0.80 | $26.3K0.5% OS | 0 |
| Jun 3, 2022 | Coiante Scott M | SVP, Chief Financial Officer | Sell | 35,284 | $0.80 | $28.4K0.5% OS | 0 |
| Jun 3, 2022 | Korbel Gregory Alan | SVP, Chief Operating Officer | Sell | 8,390 | $0.81 | $6.8K | 0 |
| Jun 3, 2022 | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 65,770 | $0.81 | $52.9K1.0% OS | 0 |
| Mar 10, 2022 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,989 | $1.82 | $3.6K | 0 |
| Feb 28, 2022 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 36,000 | $1.73 | $62.3K0.6% OS | 0 |
| Feb 25, 2022 | Coiante Scott M | SVP, Chief Financial Officer | Sell | 14,817 | $1.74 | $25.8K | 0 |
| Feb 25, 2022 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 1,326 | $1.74 | $2.3K | 0 |
| Feb 25, 2022 | SCHADE CHRISTIAN S | Chairman & CEO | Sell | 21,644 | $1.74 | $37.7K | 0 |
| Dec 1, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $3.96 | $108.9K | 0 |
| Nov 1, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $5.00 | $137.5K | 0 |
| Oct 1, 2021 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 50,000 | $4.89 | $244.5K0.8% OS | 0 |
| Oct 1, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 27,500 | $4.89 | $134.5K | 0 |
| Sep 20, 2021 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 25,000 | $4.97 | $124.3K | 0 |
| Sep 20, 2021 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 32,960 | $4.97 | $163.9K0.5% OS | 0 |
| Sep 16, 2021 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 15,968 | $4.68 | $74.7K | 0 |
| Sep 10, 2021 | Korbel Gregory Alan | Chief Business Officer | Sell | 1,724 | $4.59 | $7.9K | 0 |
| Aug 25, 2021 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 9,032 | $3.98 | $35.9K | 0 |
| Aug 25, 2021 | Coiante Scott M | SVP, Chief Financial Officer | Sell | 7,534 | $3.98 | $30.0K | 0 |
| Aug 25, 2021 | Korbel Gregory Alan | Chief Business Officer | Sell | 1,149 | $3.98 | $4.6K | 0 |
APRE Insiders
Similar Stocks to APRE
VRTX
Vertex Pharmaceuticals Incorporated
$518.01+1.45%
$131.05B
REGN
Regeneron Pharmaceuticals, Inc.
$807.38+1.09%
$81.33B
MRNA
Moderna, Inc.
$183.20+5.90%
$61.12B
RVMD
Revolution Medicines, Inc.
$192.85-0.01%
$41.87B
INSM
Insmed Incorporated
$121.67+0.57%
$26.01B
INCY
Incyte Corporation
$126.99+1.83%
$25.40B
UTHR
United Therapeutics Corporation
$497.16+0.82%
$21.00B
NBIX
Neurocrine Biosciences, Inc.
$142.39-1.09%
$14.70B